For: | Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2416-2429 [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v25/i20/2416.htm |
Number | Citing Articles |
1 |
Yan Xia, Xin Lin, Yangyang Cheng, Huimin Xu, Jingya Zeng, Wanlin Xie, Mingzhu Wang, Yihua Sun. Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.938796
|
2 |
Alexia Paturel, Janet Hall, Isabelle Chemin. Poly(ADP-Ribose) Polymerase Inhibition as a Promising Approach for Hepatocellular Carcinoma Therapy. Cancers 2022; 14(15): 3806 doi: 10.3390/cancers14153806
|
3 |
David Tai, Su Pin Choo, Valerie Chew. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers 2019; 11(12): 1926 doi: 10.3390/cancers11121926
|
4 |
Sajad Shafiekhani, Nematollah Gheibi, Azam Janati Esfahani. Combination of anti-PD-L1 and radiotherapy in hepatocellular carcinoma: a mathematical model with uncertain parameters. SIMULATION 2023; 99(4): 313 doi: 10.1177/00375497221133846
|
5 |
Min ren, Bei Fan, Guangcai Cao, Rongrong Zong, Liaoliao Feng, Huiru Sun. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer. BMC Genomics 2023; 24(1) doi: 10.1186/s12864-023-09876-3
|
6 |
Sunmin Park, Won Sup Yoon, Mi Hee Jang, Chai Hong Rim. Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinoma. International Journal of Radiation Biology 2020; 96(12): 1541 doi: 10.1080/09553002.2020.1830316
|
7 |
Ann-Lii Cheng, Chiun Hsu, Stephen L. Chan, Su-Pin Choo, Masatoshi Kudo. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. Journal of Hepatology 2020; 72(2): 307 doi: 10.1016/j.jhep.2019.09.025
|
8 |
Peng Zeng, Duo Shen, Wenbin Shu, Shudan Min, Min Shu, Xijuan Yao, Yong Wang, Rong Chen. Identification of a novel peptide targeting TIGIT to evaluate immunomodulation of 125I seed brachytherapy in HCC by near-infrared fluorescence. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1143266
|
9 |
Sung-Won Shin, Kyungmi Yang, Miso Lee, Jiyoung Moon, Arang Son, Yeeun Kim, Suha Choi, Do-hyung Kim, Changhoon Choi, Nohyun Lee, Hee Chul Park. Manganese Ferrite Nanoparticles Enhance the Sensitivity of Hepa1-6 Hepatocellular Carcinoma to Radiation by Remodeling Tumor Microenvironments. International Journal of Molecular Sciences 2021; 22(5): 2637 doi: 10.3390/ijms22052637
|
10 |
Luis A. Pérez-Romasanta, Elisabet González-Del Portillo, Ana Rodríguez-Gutiérrez, Ángela Matías-Pérez. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers 2021; 13(2): 192 doi: 10.3390/cancers13020192
|
11 |
Kyoung‐Jin Kim, Hye Won Lee, Jinsil Seong. Combination therapy with anti‐T‐cell immunoglobulin and mucin‐domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2021; 36(5): 1357 doi: 10.1111/jgh.15319
|
12 |
Ning Sun, Jialin Zhang, Baifeng Li, Ailin Li, Mutian Lv, Chengshuo Zhang. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis. Medicine 2021; 100(49): e27987 doi: 10.1097/MD.0000000000027987
|
13 |
Thomas Helmberger. The evolution of interventional oncology in the 21st century. The British Journal of Radiology 2020; 93(1113) doi: 10.1259/bjr.20200112
|
14 |
Hye Won Lee, Kyung Joo Cho, Jun Yong Park. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?. Immune Network 2020; 20(1) doi: 10.4110/in.2020.20.e11
|
15 |
Fang Fang, Bin Qiu, Peng Zhen, Junjie Wang. Hypofractionated Radiotherapy for Palliation of Main Portal Vein Tumor Thrombosis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.882272
|
16 |
Han Ah Lee, Chai Hong Rim. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. Journal of Hepatocellular Carcinoma 2020; : 435 doi: 10.2147/JHC.S285357
|
17 |
Jianing Ma, Yuning Xin, Qiang Wang, Lijuan Ding. Roles of cGAS-STING Pathway in Radiotherapy Combined with Immunotherapy for Hepatocellular Carcinoma. Molecular Cancer Therapeutics 2024; 23(4): 447 doi: 10.1158/1535-7163.MCT-23-0373
|
18 |
Heather Nesbitt, Keiran Logan, Keith Thomas, Bridgeen Callan, Jinhui Gao, Thomas McKaig, Mark Taylor, Mark Love, Eleanor Stride, Anthony P. McHale, John F. Callan. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Cancer Letters 2021; 517: 88 doi: 10.1016/j.canlet.2021.06.003
|
19 |
Kyungmi Yang, Changhoon Choi, Hayeong Cho, Won-Gyun Ahn, Shin-Yeong Kim, Sung-Won Shin, Yeeun Kim, Taekyu Jang, Nohyun Lee, Hee Chul Park. Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics 2021; 13(11): 1811 doi: 10.3390/pharmaceutics13111811
|
20 |
Liang-Cheng Chen, Hon-Yi Lin, Shih-Kai Hung, Wen-Yen Chiou, Moon-Sing Lee. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World Journal of Gastroenterology 2021; 27(20): 2434-2457 doi: 10.3748/wjg.v27.i20.2434
|
21 |
Francesca Romana Ponziani, Francesco Santopaolo, Alessandro Posa, Maurizio Pompili, Alessandro Tanzilli, Marta Maestri, Maria Pallozzi, Francesca Ibba, Riccardo Manfredi, Antonio Gasbarrini, Roberto Iezzi. SIRT in 2025. CardioVascular and Interventional Radiology 2022; 45(11): 1622 doi: 10.1007/s00270-022-03228-6
|
22 |
Hailong Sheng, Yan Huang, Yazhi Xiao, Zhenru Zhu, Mengying Shen, Peitao Zhou, Zeqin Guo, Jian Wang, Hui Wang, Wencong Dai, Wanjun Zhang, Jingyuan Sun, Chuanhui Cao. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer 2020; 8(1): e000340 doi: 10.1136/jitc-2019-000340
|
23 |
Jun Won Kim, Ik Jae Lee. Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma. Clinical and Molecular Hepatology 2021; 27(1): 103 doi: 10.3350/cmh.2020.0297
|
24 |
Dexi Zhou, Jiajie Luan, Cheng Huang, Jun Li. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?. Gut and Liver 2021; 15(4): 500 doi: 10.5009/gnl20223
|
25 |
Chun-Chia Cheng, Ai-Sheng Ho, Cheng-Liang Peng, Jungshan Chang, Zong-Lin Sie, Chih-Liang Wang, Yi-Li Chen, Cheng-Yi Chen. Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma. International Immunopharmacology 2022; 112: 109110 doi: 10.1016/j.intimp.2022.109110
|
26 |
Yuting Qian, Long Gong, Su Li, Kun Mao, Xianming Li, Guixiang Liao. Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.879454
|
27 |
Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park. Current role of proton beam therapy in patients with hepatocellular carcinoma. International Journal of Gastrointestinal Intervention 2021; 10(4): 175 doi: 10.18528/ijgii210043
|
28 |
Zhihuai Wang, Adeel Ur Rehman, Xihu Qin, Chunfu Zhu, Siyuan Wu, Ihtisham Bukhari. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022; 2022: 1 doi: 10.1155/2022/7545666
|
29 |
Pil Soo Sung. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma. Clinical and Molecular Hepatology 2022; 28(3): 333 doi: 10.3350/cmh.2021.0308
|
30 |
Qingqing Xie, Pengfei Zhang, Yuanyuan Wang, Wuxuan Mei, Changchun Zeng. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.958720
|
31 |
Edo Kon, Itai Benhar. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resistance Updates 2019; 45: 13 doi: 10.1016/j.drup.2019.07.004
|
32 |
Yasuteru Kondo, Tatsuki Morosawa, Soichiro Minami, Yasuhito Tanaka. DEB-TACE combined with hepatic artery infusion chemotherapy might be an affordable treatment option for advanced stage of HCC. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-21472-1
|
33 |
Wonmo Sung, Theodore S. Hong, Mark C. Poznansky, Harald Paganetti, Clemens Grassberger. Mathematical Modeling to Simulate the Effect of Adding Radiation Therapy to Immunotherapy and Application to Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2022; 112(4): 1055 doi: 10.1016/j.ijrobp.2021.11.008
|
34 |
Lingling Zhu, Xianzhe Yu, Li Wang, Jiewei Liu, Zihan Qu, Honge Zhang, Lu Li, Jiang Chen, Qinghua Zhou. Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges. Oncogenesis 2021; 10(7) doi: 10.1038/s41389-021-00335-w
|
35 |
Marta Maestri, Maria Pallozzi, Francesco Santopaolo, Lucia Cerrito, Maurizio Pompili, Antonio Gasbarrini, Francesca Romana Ponziani. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs 2022; 31(4): 347 doi: 10.1080/13543784.2022.2033208
|
36 |
Bahman Abedi Kiasari, Arash Abbasi, Nadia Ghasemi Darestani, Nasim Adabi, Arsalan Moradian, Yalda Yazdani, Golsa Sadat Hosseini, Nasrin Gholami, Sheida Janati. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology 2022; 113: 109365 doi: 10.1016/j.intimp.2022.109365
|
37 |
Qian Xu, Huiya Ying, Chunming Xie, Rong Lin, Yangjin Huang, Ruhuang Zhu, Yuejuan Liao, Yuan Zeng, Fujun Yu. Characterization of neutrophil extracellular traps related gene pair for predicting prognosis in hepatocellular carcinoma. The Journal of Gene Medicine 2023; 25(11) doi: 10.1002/jgm.3551
|
38 |
Mahsa Pourhamzeh, Samieh Asadian, Hamed Mirzaei, Azita Minaei, Elahe Shahriari, Anastasia Shpichka, Hamidreza Aboulkheyr Es, Peter Timashev, Moustapha Hassan, Massoud Vosough. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Molecular and Cellular Biochemistry 2023; 478(1): 23 doi: 10.1007/s11010-022-04483-4
|
39 |
Jin Hee Park, Hee Yeon Kim, Anbok Lee, Young Kyeong Seo, Il-Hwan Kim, Eun-tae Park, Mi Seon Kang, Sung Jae Park, SaeGwang Park. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1. International Journal of Radiation Oncology*Biology*Physics 2021; 110(2): 510 doi: 10.1016/j.ijrobp.2020.12.031
|
40 |
Han Ah Lee, Sunmin Park, Yeon Seok Seo, Won Sup Yoon, In‐Soo Shin, Chai Hong Rim. Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis. Journal of Hepato-Biliary-Pancreatic Sciences 2021; 28(12): 1031 doi: 10.1002/jhbp.865
|
41 |
Antonio D'Alessio, Lorenza Rimassa, Alessio Cortellini, David James Pinato. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. Journal of Hepatocellular Carcinoma 2021; : 887 doi: 10.2147/JHC.S284440
|
42 |
Zhongxiang Du, Qi Zhang, Jie Yang. Prognostic related gene index for predicting survival and immunotherapeutic effect of hepatocellular carcinoma. Medicine 2023; 102(44): e35820 doi: 10.1097/MD.0000000000035820
|
43 |
Vincenzo Quagliariello, Margherita Passariello, Domenica Rea, Antonio Barbieri, Martina Iovine, Annamaria Bonelli, Antonietta Caronna, Gerardo Botti, Claudia De Lorenzo, Nicola Maurea. Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. Journal of Personalized Medicine 2020; 10(4): 179 doi: 10.3390/jpm10040179
|
44 |
Wenzhe Yin, Jun Xu, Chao Li, Xiankui Dai, Tong Wu, Jifeng Wen. Plantamajoside inhibits the proliferation and epithelial‐to‐mesenchymal transition in hepatocellular carcinoma cells via modulating hypoxia‐inducible factor‐1α‐dependent gene expression. Cell Biology International 2020; 44(8): 1616 doi: 10.1002/cbin.11354
|
45 |
Changhoon Choi, Yeonwoo Cho, Arang Son, Sung-Won Shin, Yeon-Ju Lee, Hee Chul Park. Therapeutic Potential of (−)-Agelamide D, a Diterpene Alkaloid from the Marine Sponge Agelas sp., as a Natural Radiosensitizer in Hepatocellular Carcinoma Models. Marine Drugs 2020; 18(10): 500 doi: 10.3390/md18100500
|
46 |
Magalie Dosset, Elodie Lauret-Marie Joseph, Thaiz Rivera Vargas, Lionel Apetoh. Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells 2020; 9(7): 1727 doi: 10.3390/cells9071727
|
47 |
Nalee Kim, Jeong Il Yu, Hee Chul Park, Gyu Sang Yoo, Changhoon Choi, Jung Yong Hong, Ho Yeong Lim, Jeeyun Lee, Moon Seok Choi, Jung Eun Lee, Kyunga Kim. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunology, Immunotherapy 2021; 70(6): 1593 doi: 10.1007/s00262-020-02794-3
|
48 |
Chai Hong Rim, Hye Yoon Lee, Jung Sun Kim, Hakyoung Kim. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?. International Journal of Radiation Biology 2021; 97(2): 111 doi: 10.1080/09553002.2021.1857453
|
49 |
Kaixiao Zhou, Yabo Jiang, Shuang Feng, Tingya Wang, Lili Wang, Jianping Cao, Yang Jiao. Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy. Radiation Medicine and Protection 2022; 3(4): 183 doi: 10.1016/j.radmp.2022.07.005
|
50 |
Chou-Yi Hsu, Mohammed Ahmed Mustafa, Ashwani Kumar, Atreyi Pramanik, Rajiv Sharma, Faraj Mohammed, Israa Abed Jawad, Imad Jasim Mohammed, Mohammad Y. Alshahrani, Noor Alhuda Mohammad Ali khalil, Ali Turki Shnishil, Munther Kadhim Abosaoda. Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles. Pathology - Research and Practice 2024; 256: 155266 doi: 10.1016/j.prp.2024.155266
|
51 |
Yvonne Chiung-Fang Hsu, Jason Chia-Hsien Cheng. Radiotherapy of Liver Cancer. 2021; : 325 doi: 10.1007/978-981-16-1815-4_23
|
52 |
Yi Dong Lin, Gui Shu Wu, Ming Yue Rao, Yu Hong Liu, Yun Wei Han, Jing Zhang, Jian Wen Zhang. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-62523-z
|
53 |
Marine Valery, Baptiste Cervantes, Ramy Samaha, Maximiliano Gelli, Cristina Smolenschi, Alina Fuerea, Lambros Tselikas, Caroline Klotz-Prieux, Antoine Hollebecque, Valérie Boige, Michel Ducreux. Immunotherapy and Hepatocellular Cancer: Where Are We Now?. Cancers 2022; 14(18): 4523 doi: 10.3390/cancers14184523
|
54 |
Mehmet Eşref ALKIŞ, Sefa YEŞİLBAŞ. Effect of electroporation on radiotherapy treatment in human hepatocellular carcinoma cells. Journal of Physical Chemistry and Functional Materials 2021; 4(2): 17 doi: 10.54565/jphcfum.1006281
|
55 |
Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jin-hong Park, Sang Min Yoon. Radiologic Response as a Prognostic Factor in Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion after Transarterial Chemoembolization and Radiotherapy. Liver Cancer 2022; 11(2): 152 doi: 10.1159/000521227
|
56 |
Hao-Tian Liu, Meng-Jie Jiang, Zhu-Jian Deng, Le Li, Jian-Li Huang, Zhen-Xiu Liu, Le-Qun Li, Jian-Hong Zhong. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.737497
|
57 |
Yifei Dai, Weijie Qiang, Kequan Lin, Yu Gui, Xun Lan, Dong Wang. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunology, Immunotherapy 2021; 70(4): 967 doi: 10.1007/s00262-020-02743-0
|
58 |
Yan Xia, Xiaolu Wang, Jie Lin, Yuan Li, Lidan Dong, Xue Liang, Huai-Yu Wang, Xia Ding, Qi Wang. Gastric cancer fibroblasts affect the effect of immunotherapy and patient prognosis by inducing micro-vascular production. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1375013
|
59 |
Fan Yang, Yan Zhao, Xiaohan Huang, Jin Zhang, Ting Zhang, Yaying Sun. A Cell Differentiation Trajectory-Related Signature for Predicting the Prognosis of Lung Adenocarcinoma. Genetics Research 2022; 2022: 1 doi: 10.1155/2022/3483498
|
60 |
Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clinical and Molecular Hepatology 2021; 27(1): 144 doi: 10.3350/cmh.2020.0095
|
61 |
Li-Bin Xu, Zhen-Guo Zhao, Song-Feng Xu, Xin-Xin Zhang, Ting Liu, Chang-You Jing, Shu-Guang Zhang, Sheng-Ji Yu. The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy. The International Journal of Biological Markers 2020; 35(3): 14 doi: 10.1177/1724600820925095
|
62 |
Rixiong Wang, Nan Lin, Binbin Mao, Qing Wu. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. Journal of Cancer Research and Clinical Oncology 2022; 148(5): 1195 doi: 10.1007/s00432-021-03716-1
|
63 |
Miao-Fen Chen, Ping-Tsung Chen, Ching-Chuan Hsieh, Chih-Chi Wang. Effect of Proton Therapy on Tumor Cell Killing and Immune Microenvironment for Hepatocellular Carcinoma. Cells 2023; 12(2): 332 doi: 10.3390/cells12020332
|